Dulaglutide: a new drug for the treatment of type 2 diabetesDONG Xian-hong, ZHU Jiang, MA Shuai2281-2283,2311
Siltuximab: a novel IL-6 monoclone antibody drug for the treatment of muticentric castleman diseaseZHANG Yu-qin, DU Xiao-li2284-2287,2329
Analysis of the situation of clinical trials for antitumor drugs supported by foreign pharmaceutical industries in ChinaCHENG Xian-kui, WU Zhi-ang2288-2294,2323
Research on the patent operation of transnational corporations based on vaccines for cervical cancer Gardasil and CervarixWANG Jing, WEI Jun, FENG Xiao-liang, WANG Chao, WEI Wei2295-2300
Application scope of drug test data protection under TRIPS and the legislative choice of ChinaYANG Li, ZHANG Da-wei, CHEN Jing, LIN Lin2301-2307,2335
Introduction of the drafting procedure of "Guidelines on Development and Evaluation of Biosimilars (drafting)"BAI Yu, WANG Hai-xue, XIE Song-mei, GAO Chen-yan, YIN Hong-zhang, LUO Jian-hui2308-2311
Analysis of N-linked glycan profile of human/murine chimeric anti-CD20 antibodies by capillary electrophoresis王文波, 王兰, 王馨, 于传飞, 张峰, 刘春雨, 陈伟, 李萌, 高凯2312-2316,2345
Optimization and application of HUVEC proliferation inhibitory assay张峰, 徐刚领, 于传飞, 王文波, 陈伟, 刘春雨, 王兰, 高凯2317-2323
Recent progress in researches for action mechanism of adjuvantsLIU Yi-bo, GENG Xing-chao, WANG Ju-feng, LI Bo2324-2329